Core Viewpoint - The company, Longshen Rongfa, has obtained a Medical Device Manufacturing License from the Gansu Provincial Drug Administration, allowing it to produce and sell its blood dialysis concentrate (powder) products, which are essential for treating acute and chronic renal failure [1] Group 1 - The acquisition of the Medical Device Manufacturing License signifies that the company's blood dialysis concentrate (powder) products are now qualified for production and market sales [1] - Blood dialysis concentrate (powder) is widely used in clinical settings for blood dialysis treatment in patients with acute and chronic renal failure [1] - This license acquisition will facilitate the company's production and operational efforts for the blood dialysis concentrate (powder) products, enhancing its industry layout and fostering new profit growth points [1] Group 2 - The development is expected to improve the company's overall market competitiveness and has positive implications for its future growth [1]